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care hospital in India. Rheumatic heart disease and primary
cardiomyopathies are also present in significant proportion. In
ADHF patients there is low use of evidence-based therapies
(ACE inhibitors/ARBs, beta-blockers) and short-term mortality is
high.
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Evaluation and assessment of rosuvastatin 40 mg
treatment in high risk dyslipidemic patients
(EARTH Study)
R. Karnik, A. Trailokya, P. Kamlesh, Q. Mukaddam, M. Naik
Medical Services Division, Abbott Healthcare Private Limited, Mumbai,
India
Background: Rosuvastatin is commonly used in the treatment of
dyslipidemia, however, studies with rosuvastatin 40 mg in Indian
patients with high cardiovascular risk are lacking.
Objective: To assess the safety and efficacy of rosuvastatin 40mg
in dyslipidemic patients with high cardiovascular risk.
Methods: In an open label, non-comparative, multicentric, post
marketing observational study, 574 Indian patients were
enrolled. Treatment was started with rosuvastatin 40 mg once
daily for one month. After one month, patients achieving target
goal of LDL-C < 70 mg/dl were shifted to rosuvastatin 20 mg once
daily for next two months and those not achieving were
continued on 40mg. At third month, patients achieving LDL-C <
70 mg/dl continued 20 mg and those not achieving the target goal
were continued on 40mg for next three months. Lipid profile was
repeated after six month. The primary evaluation parameter was
percentage of patients achieving target serum LDL-C goal < 70
mg/dl at the end of one, three and six month. The secondary
evaluation parameters included percentage reduction in serum
LDL-C, serum. total cholesterol, serum triglyceride and percent-
age increase in S. HDL-C level at the end of one, three and six
month, and effect on serum creatinine at six months. Global
assessment for efficacy and tolerability was recorded by the
doctor and patient at the end of six months. All adverse events
were also recorded.
Results: Compared to baseline, there was significant increase in
number of patients achieving serum LDL <70 mg/dl at one, three
and six months. Similarly, significant reduction in serum LDL,
total cholesterol and triglyceride level and increase in HDL was
seen at one, three and six months. There was no significant
effect on serum creatinine level. Most of the patients reported
efficacy as either excellent or good as evaluated by both doctors
and patients. Close to 95% of the patients reported tolerability as
“good” as per global evaluation of tolerability by patients as well
as doctors. Rosuvastatin was generally well tolerated. The
incidence of adverse event was 9.9% with headache, myalgia,
constipation and vomiting being the commonly reported
adverse events. All the adverse events were of mild to moderate
intensity and all of them resolved during the treatment. None of
the patient required termination of treatment because of
adverse event.
Conclusion: Rosuvastatin is effective and well tolerated medicine
for the treatment of dyslipidemic patients with high cardiovas-
cular risk.
Efficacy and safety of Telmisartan alone or in
combination with hydrochlorothiazide in patients
of essential hypertension
D.P. Singh, K. Sinha, A.K. Shrivastava, S.S. Singh
S.S. Hospital, IMS, Banaras Hindu University, Varanasi, India
Background: This study was conducted to evaluate the effect of
telmisartan or telmisartan with hydrochlorothiazide (HCTZ) with
or without patient’s education about the blood pressure (BP). This
education was focused on the reduction of body weight and
healthy life-style.
Methods: 922 patients of essential hypertension were included in
this study. The inclusion criteria were: essential hypertension
(BP140/90mmHg or BP130/80mmHg in diabetic patients), age >
18 year and treatment of hypertension with at least one of the
above anti-hypertensive drug. A total of 387 patients were treated
with telmisartan and 535 patients with telmisartan with HCTZ.
The randomization ratio for life style programme was 2:1. The life
style programme included a 30 mins structured interview and
written detailed materials focused on the healthy life style, diet
and weight reduction. Patients were followed up at 4 to 8 weeks
intervals.
Results: The decrease of BP (both systolic & diastolic) during tel-
misartan/telmisartan with HCTZ treatment was statistically
highly significant (P<0.001). The decrease of BP below 140/90
mmHg was attained in 78.55% patients treated with telmisartan
and in 66.64% patients treated with telmisartan with HCTZ. The
final BP values (both systolic and diastolic) of patients enrolled in
the life style programmewere not significant different from the BP
value in patients without the life style programme. The life-style
programme had more “normotensive” patients (73.41%) than the
patients not enrolled in the life style programme (69.70%). The
difference was not significant. The mean decrease of body weight
in the life-style programme patients was 2.64±4.11 kg, which was
significantly more than in the non-life style programme patients
(0.65±3.85 kg, p<0.05).
Conclusions: The telmisartan either alone or in combination with
hydrochlorothiazide is an effective and safe anti-hypertensive
drug. The educational programme led to the decrease of body
weight, but did not significantly change the BP values.
Efficacy and tolerance of cilnidipine in cases of
amlodipine e Induced edema in hypertensives
patients
D.P. Singh, K. Sinha, A.K. Shrivastava, S.S. Singh
S S Hospital, IMS, Banaras Hindu University, Varanasi, India
Background: Ankle oedema is a common adverse effect of
Amlodipine, a widely used L-type Calcium Channel Blocker (CCB),
seen in about 15% of patients receiving the drug. Cilnidipine is a
newer third generation L/N-type CCB and is approved for the
treatment of essential hypertension. This study was, therefore,
planned to determine whether Cilnidipine therapy can produce
resolution of Amlodipine-induced oedema while maintaining
adequate control of blood pressure.
Methods: This study was carried out on 56 patients of essential
hypertension with Amlodipine-induced oedema. Concomitant
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causes for oedema including nephropathy, cardiac failure, hepatic
cirrhosis, and hypoalbuminemia due to any other cause, were
excluded by renal and liver function tests, thyroid profile, ECG and
baseline echocardiography. Varicose veins were ruled out by
clinical examination. Amlodipine therapy was substituted in all
the cases with an efficacy e equivalent dose of Cilnidipine (5mg of
Amlodipine ¼ 10 mg of Cilnidipine). Clinical assessment of ankle
oedema and measurement of bilateral ankle circumference, body
weight, blood pressure, and pulse rate were taken at the onset of
the study and after 4 weeks of Cilnidipine therapy.
Results: Out of 56 patients included in the study, 32 (57.1%) were
male. Mean age of patients were 58 ± 9.6 yrs and average duration
of Amlodipine therapy at the time of inclusion in the study was 12
± 3.5 months. 40 (71.4%) patients were receiving the 5mg of
Amlodipine daily. At completion of the study, oedema had
resolved in all the patients. There was a significant decreases in
bilateral ankle circumference and body weight (P<0.001). There
was no significant change in mean arterial blood pressure and
pulse rate.
Conclusions: Therapy with Cilnidipine resulted in complete res-
olution of Amlodipine induced oedema in all the cases without
significant worsening of hypertension or tachycardia. Cilnidipine
is an acceptable alternative antihypertensive drug for patients
with Amlodipine induced oedema.
TNF-Alpha and IL-10 serum activity in patients
with obesity-associated arterial hypertension
depend on bronchial obstruction presence
K. Sytnyk
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Objective: Recent evidence suggests close obesity and arterial
hypertension association. Both pathological states are character-
ized by low-grade inflammation which result in adipokines
dysfunction: increased activity of proinflammatory cytokines,
such as tumor necrosis factor e a (TNF-a), interleukin-6 (IL-6) and
decreased activity of anti-inflammatory cytokines e interleukin-
10 (IL-10).
The aim of our research was study relationships between serum
TNF-a and IL-10 concentrations and external breathing function
disorders in hypertensive patients with obesity.
Methods: 55 Patients with arterial hypertension (AH) were
examined. Serum TNF-a and IL-10 levels by ELISA were detected.
All patients underwent anthropometry and spirography. Patients
were divided into 3 group depend on body mass and FEV1 means:
1 gr. e hypertensives with normal body mass; 2nd gr. e obesity-
related hypertensives without bronchial obstruction (FEV1 >80%);
3rd gr. e obesity-related hypertensives with bronchial obstruction
(FEV1 <80%).
Results: Serum TNF-a (1st gr. e 3.32 ± 1.3 pg/ml, 2nd gr. 6.37 ± 0.6
pg/ml, 3rd gr. e 13.78 ± 4.1 pg/ml; p < 0.05 in all cases) levels
increasing were found in relation to obesity and bronchial
obstruction development. IL-10 serum levels decreased depend on
obesity progression to attainminimummeans in AH patients with
obesity and bronchial obstruction syndrome (1st gr. e 9.25 ± 1.8
pg/ml, 2nd gr. e 6.57 ± 0.5 pg/ml, 3rd gr. e 4.05 ± 0.9 pg/ml; p < 0.05
in all cases).
Conclusion: Obtained data demonstrate TNF-a levels elevation
and IL-10 levels reduction with maximum changes in obesity-
associated arterial hypertension with obstructive disorders of
external breathing function. Our results suggest possibility of
TNF-a and IL-10 involving to obstructive type of ventilation dis-
orders development in the patients with AH and obesity.
Use of B-Natriuretic Peptide in detecting diastolic
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Background: The potential use of assays of BNP for detection of
diastolic abnormalities associated with alterations in blood pres-
sure has not been elucidated.
Objective: This study was designed to determine whether
increased plasma concentrations of BNP sensitively reflect
abnormal diastolic function associated with hypertension.
Methods: We studied 60 patients with a primary diagnosis of
Hypertention. All patients were studied with the use of pulsed
Doppler transmitral flow velocity and color Tissue Doppler echo-
cardiography for the evaluation of left ventricular diastolic func-
tion. Serum BNP was determined with a sandwich immunoassay
on ‘Elecys 2010. Anova / Dunnet’s t test was used when comparing
means. The diagnostic utility of BNP was compared with the
echocardiographic probability of LV dysfunction through the use
of receiver-operating characteristic (ROC) curves.
Results: Patients were divided into 2 groups on the basis of
whether they manifested normal or abnormal LV diastolic func-
tion by echocardiography. Patients diagnosed with abnormal
diastolic function had a mean BNP concentration of 285±31 pg/
mL, whereas the normal subjects had a mean BNP concentration
of 31±4 pg/mL. The difference between groups was significant (P
<0.001). The AUC for the ROC curve with BNP used to detect any
abnormal diastolic dysfunction was 0.91 (95% CI, P <0.001). A BNP
value of 62 pg/mL had a sensitivity of 85%, a specificity of 83% for
detecting diastolic dysfunction.
Conclusion: Our results suggest that the plasma BNP level is
influenced by diastolic dysfunction and an assay for BNP can
reliably detect the presence of diastolic dysfunction.
Pharmacoepidemiological surveillance of
antihypertensive therapy
Vijay Chamle, Rishi Jain
Glenmark Pharmaceuticals, Mumbai, India
Objective: The purpose of this study was to understand the usage
pattern of antihypertensive drugs and their fixed dose combina-
tion in clinical practice.
Methods: Doctors were asked to fill a questionnaire based on their
clinical experiences in dealing with patients with hypertension.
These questions were to be answered based on the doctor’s clin-
ical experience. Descriptive statistics were used to describe the
results.
Results: We collected completely filled questionnaires from 427
doctors. 46.33 % doctors in their clinical practice encounter 20- 40
newly diagnosed hypertensive patients per month. Among all the
patients with newly diagnosed hypertensive there were about 10-
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